Biomarkers: An Important Tool for Diagnosing and Treating Diabetes Mellitus

被引:2
作者
Chakraborty, Tulshi [1 ]
Gupta, Sumeet [1 ]
Saini, Vipin [2 ]
Talukdar, Arindam [1 ]
机构
[1] Maharishi Markandeshwar, MM Coll Pharm, Ambala, Haryana, India
[2] Maharishi Markandeshwar Univ, Solan, Himachal Prades, India
来源
INTERNATIONAL JOURNAL OF LIFE SCIENCE AND PHARMA RESEARCH | 2021年 / 11卷 / 02期
关键词
Diabetes mellitus; biomarkers; 1; 5-anhydroglucitol; C-reactive protein; microRNA; Haemoglobin A1C;
D O I
10.22376/ijpbs/lpr.2021.11.2.P123-129
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Diabetes mellitus is a group of metabolic disease caused by an abnormal increase in blood glucose levels due to abnormal activity of pancreatic beta cells. Elevated blood glucose levels causes a variety of cell damage, including endothelial cells, neurons, renal cells, keratinocytes, and fibroblasts. Chronic diabetes mellitus causes several diabetic manifestations such as diabetic neuropathy, diabetic nephropathy, diabetic myopathy, and diabetic dermopathy. There are many causes and risks of diabetes mellitus, including type 1 diabetes caused by bacterial infections, chemical poisoning with food, and self-resistance; Type 2 diabetes is caused by obesity, weight gain, prediabetes and family history, and type 3 is caused by Cushing's syndrome. Diabetes mellitus treatment has encountered a few progressions in the previous decades with the revelation of explicit prescient prognostic biomarkers that make conceivable the use of individualized treatments. Various hypoglycemic oral and parenteral dosage formulations are used to treat diabetes mellitus, but insulin therapy is one of the most effective treatments for type 1 and type 2 diabetes and its complications. Various conventional diagnosing and treating methods of diabetes mellitus are available but there are limitations of resistance and, accuracy. For that reason now a day's various biomarkers like Autoantibodies, C-reactive protein (CRP), Fibrinogen, Interleukin-1 receptor antagonist (IL-1RA), Plasminogen activator inhibitor (PAI-1), etc. are used for diagnosis; Adiponectin, microRNA, Acylcarnitine, Haemoglobin A1c, etc. are used for treatment, and 1,5-anhydroglucitol are used for both diagnosis and treatment of diabetes mellitus. In this review, we discussed the functions, application and limitations of diabetes biomarkers in their use as diagnostic and treatment. These biomarkers are of paramount importance in the assessment and diagnosis process, leading to better care and protection of patients. Due to its various advantages, biomarkers are considered as an innovative tool in the advancement of diagnosis and treatment of diabetes mellitus.y
引用
收藏
页码:P123 / P129
页数:7
相关论文
共 30 条
  • [1] Aggarwal J, 2019, INT J RES MED SCI, V7, P4340
  • [2] Alsaimary IEA, 2010, INT J MICROBIOL, V7, P12
  • [3] Heart rate variability and plasma biomarkers in patients with type 1 diabetes mellitus: Effect of a bout of aerobic exercise
    Anaruma, Chadi P.
    Ferreira, Maycon, Jr.
    Sponton, Carlos H. G.
    Delbin, Maria A.
    Zanesco, Angelina
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 111 : 19 - 27
  • [4] Babrak Lmar M, 2019, Digit Biomark, V3, P92, DOI 10.1159/000502000
  • [5] A Review of the Application of Inflammatory Biomarkers in Epidemiologic Cancer Research
    Brenner, Darren R.
    Scherer, Dominique
    Muir, Kenneth
    Schildkraut, Joellen
    Boffetta, Paolo
    Spitz, Margaret R.
    Le Marchand, Loic
    Chan, Andrew T.
    Goode, Ellen L.
    Ulrich, Cornelia M.
    Hung, Rayjean J.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (09) : 1729 - 1751
  • [6] Buse John B, 2003, Diabetes Technol Ther, V5, P355, DOI 10.1089/152091503765691839
  • [7] Chakraborty. T., 2020, Research Journal of Pharmacy and Technology, V13, P4115, DOI 10.5958/0974-360X.2020.00727.1
  • [8] Chandalia HB, 2002, CURR SCI INDIA, V83, P1522
  • [9] Diwaker Amita, 2019, J Assoc Physicians India, V67, P65
  • [10] Dorcely Brenda, 2017, Diabetes Metab Syndr Obes, V10, P345, DOI 10.2147/DMSO.S100074